Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Motor Activity 19Polycystic Ovary Syndrome 10Prostatic Neoplasms 7Breast Neoplasms 6Neoplasms 5Colorectal Neoplasms 4Insulin Resistance 3Lung Neoplasms 2Fatigue 2Esophageal Neoplasms 2Cardiotoxicity 2Stomach Neoplasms 1Rectal Neoplasms 1Primary Dysautonomias 1Pediatric Brain Tumor 1Ovarian Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Lymphoma, Follicular 1Lupus Erythematosus, Systemic 1Inflammation 1Hodgkin Disease 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Disease 1Diabetes Mellitus, Type 1 1Chemotherapy-Related Cognitive Impairment 1Cardiovascular Diseases 1Carcinoma, Hepatocellular 1Cachexia 1

Interventions

High-Intensity Interval Training 1Exercise 1Cholecalciferol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Lupus Erythematosus, Systemic × High-Intensity Interval Training × Clear all
NCT05478018 2025-09-09

LUPEX

Rigshospitalet, Denmark

Phase NA Completed
55 enrolled

Lupus Erythematosus, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡